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i.  Abstract 
The genome of mammals harbors chemical modifications at some cytosine 
residues in the form of a methyl group.  These modified residues, termed 5’-
methylcytosines, have been discovered more than 50 years ago (Hotchkiss 1948) and 
have since been shown to play important roles in the regulation of gene expression and 
in the execution of developmental programs.  Patterns of cytosine methylation (also 
referred to as DNA methylation) are carefully set and preserved during cellular expansion 
and global methylation levels are well regulated throughout development.  Changes in 
methylation patterns and levels have been associated with disease progression and 
death (Li et al. 1992; Okano et al. 1999; Ehrlich 2002).  Specifically, elevated levels of 
global genomic methylation have been shown to play a role in the inactivation of tumor 
suppressor genes in many types of cancer (Ehrlich 2002).  In contrast, reduced levels of 
methylation have been observed in a wide variety of tumors and complete 
demethylation in vivo causes embryonic death (Li et al. 1992; Ehrlich 2002). 
 
 
In an effort to study the effect of changed methylation levels in vivo and its effect 
on disease progression, we developed a genetic approach to study the effect of 
hypomethylation during embryogenesis and adulthood.  DNA methyltransferase 1 
(Dnmt1) is the major methyltransferase in mammals and genetic inactivation of the 
Dnmt1 gene causes demethylation that results in cell death in tissue culture and 
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embryonic lethality of homozygous mutant mice at E8.5 (Li et al. 1992).  In a first step, 
the 5’ end of the Dnmt1 gene was characterized to determine the structure of a new 
oocyte-specific isoform found in oocytes and early embryos.  Upon elucidation of the 
structure of this isoform, assays were developed to test its function in vivo.  Loss of this 
oocyte-specific isoform protein resulted in hypomethylation of an IAP reporter element 
suggesting a role for this protein in early development.  In contrast, the somatic Dnmt1 
isoform, which is present in all somatic cells, was important for maintaining this IAP 
element methylated following implantation of the embryo and throughout adulthood.  
Reduced levels of Dnmt1 in adults caused global hypomethylation and resulted in the 
development of thymic lymphomas which displayed a duplication of chromosome 15 
(trisomic 15).  The c-myc oncogene, which resides on chromosome 15, was 
overexpressed, and a gene expression array analysis revealed that another oncogene, 
Notch-1, was also overexpressed in all tumors.  Cooperation between those oncogenes 
has been previously shown to induce thymic lymphomas.  Analysis of the Notch-1 locus 
demonstrated the presence of IAP insertions upstream of the oncogenic cytoplasmic 
domain capable of activating transcription of truncated oncogenic Notch-1.  IAP elements 
were shown to be activated by hypomethylation albeit not as much as traditional 
mutagenic retroviruses.  These results thus show that hypomethylation may induce 
tumorigenesis in this model following two mechanisms.  First by inducing chromosome 
instability and second by creating insertional mutagenesis of defective retroviral 
elements such as IAPs.  These results demonstrate for the first time that 
hypomethylation can directly induce tumorigenesis in mice and induce chromosome 
instability. 
 8
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Chapter 1 
 
 
Introduction 
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1.1. A fifth DNA base 
 
Developmental stages in mammals are established by genetic and epigenetic 
programs.  Epigenetic information is defined as those marks which are inherited through 
mitosis or meiosis but are independent of the DNA sequence.  They constitute signals 
that are interpreted to regulate gene expression and cellular differentiation. The most 
common of these marks is DNA methylation, which consists in the addition of a methyl 
group to the 5’ carbon of cytosine residues (Figure 1).  Cytosine-5 methylation is present 
in vertebrates, vascular plants and other eukaryotes and prokaryotes.   
   
 
 
Figure 1. The methylation reaction.  The enzyme first binds covalently to the 6’ carbon of the 
cytosine ring via a cysteine thiol group on the enzyme.  The binding causes an electron transfer 
from the C-5/C-6 double bond to the 5’ carbon.  The energetic doublet on the 5’ carbon then 
attacks the carbon from the methionine moiety of S-adenosyl L-methionine, resulting in the 
transfer of a methyl group from SAM to the 5’ carbon of the cytosine and the release of S-
adenosyl-L-homocysteine.  The release of the enzyme is achieved by the attack and capture of a 
proton on C-6 by a base, recreating the C-5/C-6 double bond and resulting in 5-methyl cytosine 
(Gerlt and Gassman, 1993).   
 
 
The biological significance of this epigenetic modification was established in 1992 
when the gene responsible for maintaining cytosine methylation was inactivated in mice, 
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resulting in genomic demethylation and death of the embryo at day E10.5 (Li,,et al. 
1992). Subsequent knockout of methyltransferase family members in mice have resulted 
in embryonic lethal phenotypes and early post-natal death, consistent with a crucial 
function for cytosine methylation in developmental regulation (Okano et al. 1999).   
 
DNA methylation has been shown to play an important role in the suppression of 
many genes including tissue-specific genes, imprinted genes and genes of the inactive X 
chromosome (Keshet et al. 1986; Becker et al. 1987; Li, Beard et al. 1993; Panning and 
Jaenisch 1996).  In addition, methylation can silence endogenous proviruses including 
SINES, LINES, IAPs and other proviruses so as to prevent insertional mutagenesis 
(Jaenisch et al. 1985; Walsh et al. 1998).  It has also been shown that methylation provides 
additional stability to the genome, perhaps by providing a more tightly packed 
chromatin that is less prone to recombination events (Colot et al. 1996; Chen et al. 1998; 
(Hashimshony et al. 2003). 
 
Cytosine methylation normally occurs in the context of the palindromic 5’-CG-3’ 
(CpG) dinucleotide (Holliday and Pugh 1975; Bird 1978).  About 70% of CpGs in 
mammalian genomes are methylated (Ehrlich et al. 1982), most of which at repetitive 
elements scattered throughout the genome (Yoder et al. 1997; Baylin and Bestor 2002).  
An interesting characteristic of CpGs is that they are greatly under-represented in the 
genome (Sved and Bird 1990).  The higher spontaneous deamination rate of 5-
methylcytosine compared to cytosine might account for this observation.  In addition, 5-
methylcytosine deaminates to thymine causing a C⇐T mutation whereas deamination of 
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cytosine creates a uracil residue that is efficiently removed by the DNA repair machinery 
thus making the former a more likely mutation site.  CpGs are mutation hotspots that 
contribute to 30% of all point mutations in the germline (Cooper and Youssoufian 1988; 
Jones et al. 1992; Laird and Jaenisch 1994).  Surely, since DNA methylation poses such a 
substantial mutagenic burden on the genome, it must contribute a strong selective 
advantage, perhaps by presenting an efficient means of regulating transcription of 
complex genomes.  
 
Several models have been proposed to explain the evolutionary advantage of 
methylation, of which two hypotheses stand out.  One hypothesis suggests that DNA 
methylation works as a silencer of background “transcriptional noise” (Bird 1995).  This 
hypothesis is supported by the fact that 1) it is restricted to large genome organisms but 
practically absent from species with smaller genomes such as Drosophila melanogaster and 
Caenorhabtidis elegans, 2) it is largely confined to intergenic, non-coding and repetitive 
regions and 3) it is absent from the promoter regions of active genes.  The other 
hypothesis argues that DNA methylation functions mainly as a defense system by 
silencing parasitic elements throughout the genome (Yoder et al. 1997). It has been 
shown that methylation silences expression of retroviral elements in somatic cells 
(Jaenisch et al. 1985; Walsh et al. 1998).  However, this hypothesis fails to explain why 
undifferentiated cells of the early embryo are hypomethylated and retroviral elements 
such as IAPs are expressed in them (Kuff and Lueders 1988; Poznanski and Calarco 
1991), leaving a possibility for these elements to become active and cause insertional 
mutagenesis.  Therefore if DNA methylation constituted a defense system uniquely in 
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somatic cells, it would not be subject to evolutionary selection because mutations 
occurring late in development would be confined to a few subset of clonal cells, making 
it unlikely to operate as an efficient defense mechanism. 
In any case, changes in patterns of methylation have been associated with disease 
progression such as ICF syndrome and cancer.  Importantly, DNA methylation is a 
stable modification that is reversible, making it ideal for regulation of developmental 
programs. Understanding the mechanisms that regulate it will provide a unique 
opportunity for therapy and intervention. 
 
 
1.2. Enzymes of DNA methylation 
 
DNA methylation patterns vary significantly throughout development.  These 
changes involve both methylation as well as demethylation activities.  While it is still 
unclear which components play an active role in genomic demethylation, cytosine 
methylation is established and maintained by DNA methyltransferases whose 
expression is tightly regulated during development.  These enzymes catalyze the 
transfer of a methyl moiety from S-adenosyl-L-methionine to the 5’ carbon of a cytosine 
pyrimidine ring (Wu and Santi 1987).  There are two distinct DNA methyltransferase 
activities: de novo methylation and maintenance methylation (Figure 2).   
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Figure 2.  Changes of methylation patterns during development.  The levels of methylation are 
relatively high in both mature gametes.  After fertilization, a global wave of passive 
demethylation takes place until implantation of the embryo after which a wave of 
remethylation occurs and somatic cells become highly methylated by EXXX.  In contrast, 
primordial germ cells remain demethylated until the beginning of gametogenesis when they 
differentiate and become methylated.  Recent findings argued that primordial germ cells are 
methylated after implantation and soon followed by a wave of demethylation (REF) but these 
results have yet to be replicated. 
 
 
1.2.1. Methylation of unmethylated DNA 
 
The methylation of previously unmethylated DNA, referred to as de novo 
methylation, is carried by two enzymes in mammals: Dnmt3a and Dnmt3b (Figure 2).  
These proteins contain well conserved motifs in the catalytic domain that are present in 
all DNA methyltransferases.  Inactivation of  Dnmt3a and Dnmt3b by gene targeting in 
ES cells abolishes the ability of these cells to de novo methylate foreign DNA (Okano et 
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al. 1999).  Both proteins are essential for normal development as Dnmt3a knockout mice 
become runted after birth and die after 4 weeks of age and Dnmt3b knockout induces 
various embryonic defects and causes death before E15.5.  Animals homozygous mutant 
for both Dnmt3a and Dnmt3b die before E11.5, a phenotype that is more severe than any 
individual phenotype, suggesting an overlapping function for these proteins in 
embryogenesis (Okano et al. 1999).  Double mutant embryos are also unable to de novo 
methylate genomic DNA following implantation of the embryo like wild-type embryos 
do.  Both de novo methyltransferases are expressed at various levels in adult somatic 
tissues suggesting that they may have distinct roles at that stage.   
 
De novo methylation may play an important function in organizing and 
compartmentalizing the genome during somatic differentiation so that genes are 
expressed in the proper sequence and cell types.  In humans, cells from ICF syndrome 
patients were shown to contain mutations in DNMT3B, and DNMT3B mutant cells were 
found to contain chromosomal abnormalities.  Additionally, several groups have 
reported overexpression of Dnmt3a and Dnmt3b in various tumors (Robertson et al. 
1999; Girault et al. 2003).  Tissue-specific inactivation and overexpression of these 
enzymes will be necessary to elucidate their function in mature organs, tissues and in 
tumorigenesis.   
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1.2.2.  Maintenance of DNA methylation patterns 
 
Following replication when the newly synthesized DNA strand is unmethylated, 
an enzyme binds to hemimethylated sites and catalyzes the transfer of a methyl group 
on the daughter strand to restore the palindromic methyl CpG configuration (Figure 2).  
This activity is catalyzed by Dnmt1, the first mammalian methyltransferase 
characterized more than 10 years ago and has been referred to as maintenance methylation.  
This methylation activity ensures that established patterns of methylation are preserved 
over many cell generations and provides a mean for heritable transcriptional control 
during development.  The somatic form of Dnmt1 contains 1581 amino acid residues, 
consisting of a regulatory N-terminus of ~1000 amino acids that is linked by a segment 
of 12 alternating glycyl and lysyl residues to a C-terminus catalytic domain of ~ 500 
amino acids that is closely related to prokaryotic cytosine methylases (Bestor et al. 1988).  
The regulatory domain contains a cysteine-rich region capable of binding zinc ions 
(Bestor 1992), a proliferating cell nuclear antigen (PCNA) binding domain (Chuang et al. 
1997), several nuclear localization sequences (Cardoso and Leonhardt 1999), a 
polybromo homology domain (Liu et al. 1998) and a targeting sequence controlling 
subnuclear localization (Leonhardt et al. 1992) whereas the catalytic domain contains the 
conserved methyltransferase motifs. Several interactions have been described between 
DNMT1 and different chromatin-associated proteins and cell cycle regulators such as 
pRb, HDACs, MeCP2, SUV39H1 and HP1-beta, and PCNA (Chuang et al. 1997; 
Robertson et al. 2000; Rountree et al. 2000; Fuks et al. 2003; Kimura and Shiota 2003).  
Homozygous gene inactivation of Dnmt1 results in demethylation in the embryos and 
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death by E9.5.  Inactivation of Dnmt1 in T cells in vivo causes a depletion of this cell type 
in the animal (Lee et al. 2001) and inactivation in fibroblasts caused cellular death after 2 
weeks in vitro (Jackson-Grusby et al. 2001) suggesting that maintenance methylation is 
necessary for cellular differentiation and expansion of differentiated cells.  Dnmt1 was 
shown to possess a maintenance activity in vivo in concert with Dnmt3a but no de novo 
activity (Lyko et al. 1999).  Interestingly, Dnmt1 null ES cells grow normally in the 
absence of Dnmt1 and primordial germ cells do not contain Dnmt1, suggesting that this 
protein is not always necessary for cell division and survival (Li et al. 1992). 
 
Dnmt1 is expressed during much of embryonic development and in the adult and 
exists as two isoforms in vivo.  A shorter isoform is present in oocytes and early embryos 
and a longer isoform is expressed in postimplantation embryos and in somatic cells.  The 
levels of the shorter isoform are very high in the oocyte and the fertilized egg and 
progressively decrease together with global methylation until embryonic implantation. 
The expression of the protein goes up again soon after implantation of the embryo 
together with the wave of de novo methylation, and remain present at various levels in 
adult tissues.  In addition, Dnmt1 overexpression has often been linked to tumorigenesis 
(Robertson et al. 1999). 
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1.2.3. Are there additional mammalian DNA methyl-
transferases? 
 
 A gene containing all the highly conserved catalytic domain methyltransferase 
motifs was identified and was termed Dnmt2 (Okano et al. 1998; Van den Wyngaert et 
al. 1998; Yoder and Bestor 1998).  However, no methyltransferase activity was found for 
this protein when it was overexpressed from a baculovirus expression vector.  In 
addition, Dnmt2 knockout in ES cells did not affect their de novo or maintenance 
methyltransferase activities (Okano et al. 1998) and genetic inactivation of Dnmt2 in mice 
did not result in any detectable phenotype.  The function of Dnmt2 remains to be 
determined.  A protein called Dnmt3L was isolated and was found to play a role in the 
setting of imprints in oocytes.  This protein does not contain the conserved 
methyltransferase motifs and has no known enzymatic activity.  The genome of 
primordial germ cells becomes methylated as the gametes differentiate.  In addition, 
genomic imprints are known to be set in the gametes, but the factors necessary to 
conduct these functions remain to be identified (Margot et al. 2003; Bourc’his et al. 2001).  
 
1.2.4. Genomic demethylation 
 
Passive demethylation of the DNA can occur when methyl groups fail to be 
added onto the new DNA strand following DNA replication.  This can happen when 
proper cellular maintenance methyltransferase activities are impaired such as when 5-
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azacytidine is present (Jones 1984) or when a loxed (Cre/ lox) Dnmt1 gene is looped out 
and inactivated in tissue culture (Jackson-Grusby et al. 2001).  Such demethylation was 
shown to cause the activation of retroelements and developmentally regulated genes in 
the cultured cells (Jackson-Grusby et al. 2001).  In addition, passive demethylation is 
thought to occur in early embryogenesis when the levels of Dnmt1 decrease and become 
mostly localized in the cytoplasm (Carlson et al. 1992; Rougier et al. 1998; Cardoso and 
Leonhardt 1999).  Active demethylation (independent of DNA replication) has been 
shown following induction of the vitellogenin gene in chick liver (Wilks et al. 1984) or of 
the globin gene in erythroleukemia cells (Razin et al. 1984) and has also been observed in 
transiently transfected myoblasts (Paroush et al. 1990), in postmeiotic spermatocytes 
(Trasler, Hake et al. 1990) and in preimplantation mouse embryos (Kafri et al. 1993). 
Recently, active demethylation has been shown to occur on the paternal genome soon 
after fertilization (Mayer et al. 2000; Oswald et al. 2000) by an unknown mechanism.  It 
has been suggested that active demethylation is at least partly mediated by an RNA 
component and that demethylation occurs by the removal of DNA nucleotides after their 
conversion to RNase-sensitive molecules (Weiss et al. 1996). Surely, additional 
components remain to be identified.  More recently, active demethylation of the Il-2 
promoter was shown in T cells following their activation (Bruniquel and Schwartz 2003).  
The mechanism of demethylation in this case is unknown and research is intensifying to 
characterize components responsible for these activities. 
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1.3. Dynamics of DNA methylation 
changes during development 
 
Overall degrees of genomic methylation vary substantially during development 
and methylation level changes are well coordinated with developmental stages.  In early 
embryogenesis, the levels of genomic methylation progressively decrease until 
implantation, and shortly thereafter are increased until the DNA is highly methylated in 
somatic cells.  In contrast to embryogenesis, the levels of methylation in somatic lineages 
remain fairly stable throughout development.  The significance of these global changes 
of methylation during embryogenesis are unknown but may serve as a way to 
reprogram the genome to suppress early developmental gene expression after 
implantation and to make accessible the loci needed for subsequent lineage-specific 
differences (Figure 3). 
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Figure 3.  Regulation of DNA methylation by DNA methyltransferases.  The major de novo 
methyltransferases Dnmt3a and Dnmt3b can use unmethylated CpG as substrates to create a double-
stranded methylated CpG dinucleotide.  This pattern is lost following DNA methylation as the newly 
synthesized strand is unmethylated.  This hemimethylated CpG becomes a substrate for the 
maintenance methyltransferase Dnmt1 soon after replication of the DNA strand and restores the fully 
methylated configuration. 
 
 
1.3.1.  Changes of DNA methylation levels during gameto-
genesis 
 
As gametogenesis begins, the demethylated primordial germ cells undergo a wave of 
methylation that coincide with cellular differentiation.  During this process, imprinted patterns are 
established in both parental gametes.  During gametogenesis, the genome becomes methylated 
and imprinted gene methylation is set.  An enzyme that bears resemblance to Dnmt3 (termed 
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Dnmt3L for Dnmt3-like) is expressed at that time and is responsible for setting the imprints in 
oocytes (Howell et al. 2001). Imprinted genes are genes whose allelic expression is determined by 
the parental origin (Bartolomei and Tilghman 1997; Jaenisch 1997).  Dnmt3L lacks the highly 
conserved methyltransferase motifs and has no enzymatic activity.  Dnmt1 is present at high 
levels in mature oocytes and is sequestered in the cytoplasm and it is not clear whether it has a 
function in setting the imprints.  Dnmt3L is also expressed in the male gamete and Dnmt3L 
homozygous knockout is incompatible with spermatogenesis (Howell et al. 2001).  In contrast, 
the mature sperm is devoid of Dnmt1 but although Dnmt1 is found in the nucleus of leptotene to 
pachytene stage spermatocytes (Mertineit et al. 1998). A few loci have been described that escape 
this global wave of reprogramming.  For example, the methylation status of the mouse Aiapy allele 
can be inherited in the next generation.  This event, termed transgenerational inheritance of 
epigenetic states, has been observed in mice at a variety of loci and circumstantial evidence 
suggests that this process may also occur in humans (Morgan et al. 1999; Greally 2002).  
 
 
1.3.2.  Changes of DNA methylation levels during embryo-
genesis  
 
After fertilization, the paternal genome soon becomes actively demethylated 
(Mayer et al. 2000; Oswald et al. 2000) followed by passive demethylation of both the 
maternal and paternal genomes (Monk et al. 1987; Kafri et al. 1992; Rougier et al. 1998).  
This demethylation occurs in the bulk DNA which consists of repetitive elements and 
most gene sequences.  This period is associated with a progressive loss of Dnmt1 and by 
its localization in the cytoplasm the vast majority of the time.  The embryo becomes 
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further demethylated until the postimplantation stage when a wave of remethylation 
occurs as a result of the expression of the de novo methyltransferases Dnmt3a and 
Dnmt3b and the maintenance methyltransferase Dnmt1.  The levels of methylation 
remain high in somatic cells except in the germ cell lineage where the degree of 
methylation stays low until gametogenesis.  
 
In contrast to bulk DNA, the methylation of imprinted genes and CpG islands are 
affected quite differently.  The methylation of imprinted genes is established during 
gametogenesis and remain resistant to demethylation or de novo methylation in 
embryogenesis and in adulthood.  The only exception is the differentiating germ cells 
which have the ability to reprogram imprinted genes (Tucker et al. 1996). CpG islands 
are unmethylated in normal cells except on the inactive X chromosome of female cells 
(Bird 1987).  They reside in the proximity of promoters or first exons, are usually 1-2 k 
long, and are associated with housekeeping genes (Bird 1987).  These islands are 
estimated at 45 000 copies, are associated with 60% of genes (Gonzalgo and Jones 1997) 
and contain the predicted frequency of CpGs of 12.5%, representing 15% of all CpG sites.  
They have an open chromatin structure that is deficient in the linker histone H1 and 
contain nucleosomes enriched in acetylated forms of histones H3 and H4 that are 
associated with active chromatin.  It has been suggested that transcriptional silencing 
may be necessary for DNA methylation to occur and that genes containing CpG islands 
are not silenced in post-implantation embryogenesis when the embryo becomes 
methylated, making them resistant to DNA methylation (Bird 2002). CpG islands can be 
classified in three categories.  
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The CpG islands associated with housekeeping genes on chromosome X are 
methylated upon inactivation of the chromosome and those patterns of methylation are 
stably inherited after each cell division.  The CpG islands associated with tumor 
suppressor genes are unmethylated in normal tissues but often become methylated as 
tumors develop (Laird and Jaenisch 1994; Baylin et al. 1998) and may play a role in 
tumorigenesis (Myohanen et al. 1998).  All other CpG islands are unmethylated during 
development.  This resistance to methylation was shown to be dependent on an intact 
Sp1 binding site within CpG islands (Brandeis et al. 1994).  In addition to housekeeping 
genes which contain CpG islands, about 50% of tissue-specific genes also contain CpG 
islands (Jones, P.A. 1999). 
 
1.4. Interpretation of DNA methylation 
signals 
 
The most common effect of DNA methylation is gene silencing.  This process 
represents a unique mechanism of gene regulation because it is both reversible and 
stable.  Patterns of methylation can be modulated through development resulting in 
activation or inactivation of proper developmental programs.  The stability of this 
modification makes it quite energy-efficient as they can be inherited though mitotic cell 
division.  In fact, cell culture experiments have shown that the stability of the 
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modification approaches the genetic point mutation frequency of DNA (Harris 1982; 
Holliday 1990).  The silencing of gene expression by DNA methylation is achieved by a 
number of proteins including methyl-binding proteins and chromatin remodeling 
proteins that can read the methylation status and alter gene transcription.  
 
1.4.1. Numerous genes and elements are regulated by DNA 
methylation 
 
The expression of many genes and DNA elements is modulated by DNA 
methylation.  For example, imprinted genes possess DNA methylation marks that allow 
allele-specific expression (Bartolomei and Tilghman 1997; Jaenisch 1997).  These marks 
are set during gametogenesis and are maintained throughout life.  Failure to properly 
maintain methylation patterns at imprinted gene loci results in either biallelic expression 
or complete loss of expression (Li et al. 1993; Tucker et al. 1996; Caspary et al. 1998).  The 
expression of the Xist gene, which is involved in chromosome X inactivation, also 
correlates with DNA methylation.  Demethylated Dnmt1 mutant embryos activate Xist 
which induces inactivation of the active X chromosome, resulting in silencing of both X 
chromosomes (Panning and Jaenisch 1996).  Proper regulation of X inactivation is very 
important to compensate for the different dosage of X-linked genes between males and 
females and is achieved by the random inactivation of an X chromosome in females.  In 
addition to these genes, the expression of many tissue-specific genes correlates with the 
methylation status of their promoters regions (Eden and Cedar 1994).  Methylation 
generally correlates with gene silencing whereas demethylation is associated with 
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transcriptional activation.  Finally, endogenous retroviruses and other transposable 
elements are also silenced by methylation (Jähner 1984).  These sequences are normally 
methylated and transcriptionally silent.  Hypomethylation induced by hypomethylating 
drugs or by genetic inactivation of Dnmt1 results in the activation of endogenous viruses 
in vitro and in vivo (Jaenisch et al. 1985; Walsh et al. 1998). 
 
While it is widely known that methylation can affect gene expression, the 
mechanisms by which methylation exerts its effect on transcriptional activity has become 
more clear only recently.  Methylation signals can be interpreted through several 
mechanisms to inhibit specific genes or genomic regions so as to signal specific cellular 
or developmental programs. 
 
1.4.2.  DNA methylation can prevent the binding of trans-
cription factors to their recognition sequence 
 
Methylation can physically prevent transcription factors from binding to their 
recognition sequences (Watt and Molloy 1988) although this type of regulation is rather 
uncommon in vivo (Takizawa et al. 2001).  For example, the glial fibrillary acidic protein 
(GFAP) gene is activated during astrocyte differentiation by the demethylation of a CpG 
dinucleotide located in a STAT3 (signal transducer and activator of transcription 3) –
binding element (Takizawa et al. 2001).  While the end result of methylation is generally 
transcriptional silencing, methylation of repressor protein-binding elements in the 
imprinted insulin-like growth factor 2 (Igf2) gene can increase its expression (Eden et al. 
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2001; Murrell et al. 2001).  In addition, methylation of a CTCF binding site on the 
paternal allele of Igf2 prevents the binding of the repressor protein and allows the H19 
enhancer to promote Igf2 transcription.  In contrast, hypomethylation of the CTCF 
binding site on the maternal allele allows binding of the repressor to this site and isolates 
the H19 enhancer, resulting in Igf2 silencing (Bell and Felsenfeld 2000; Hark et al. 2000).  
In any case, methylation of such recognition sites does not necessarily prevent target 
proteins from binding to the DNA (Brandeis et al. 1994; Macleod D et al. 1994). 
 
1.4.3.  Transcriptional repressors can bind to methylated DNA 
and induce chromatin remodeling 
 
Methylation signals can be interpreted directly by methyl-CpG-binding proteins 
(MeCPs) that can alter gene transcription.  There are 5 known MeCPs in mammals (Nan 
et al. 1993; Cross et al. 1997; Hendrich and Bird 1998; Prokhortchouk et al. 2001).  Four of 
these proteins, MeCP2, MBD1, MBD2 and MBD4 bind methyl-CpGs through a 
conserved protein motif called the methyl-CpG binding domain (MBD, (Nan et al. 
1996)).  Another MeCP, Kaiso, differs from the other 4 by binding to methyl-CpGs 
through a zinc finger binding domain (Prokhortchouk et al. 2001). MBD3 also contains 
the MBD but does not have the ability to bind to methylated DNA (Hendrich and Bird 
1998).  All MeCPs except MBD4 have been shown to act as transcriptional repressors in 
vitro (Hendrich and Bird 1998). In contrast, MBD4 has been implicated in DNA repair 
(Bellacosa et al. 1999; Hendrich et al. 1999) and may act to minimize mutations at 5-
methylcytosine.  The repression activity of MeCPs is largely achieved by their interaction 
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with histone deacetylase complexes (Prokhortchouk et al. 2001) that help condense the 
chromatin into higher order structures that are transcriptionally silent.  For example, 
MeCP2 forms a complex with histone deacetylases and the co-factor protein Sin3a to 
repress transcription after binding methyl-CpG (Nan, X., et al, Nature, 393, p.386, 1998; 
Jones, P.L. et al, Nature Genet., 19, p.187, 1998).  Another complex made of the methyl-
CpG-binding protein MBD2 and the multisubunit NuRD (previously known as MeCP1) 
can repress transcription in a similar fashion.  The NuRD complex contains the ATP-
dependent chromatin remodeling protein Mi-2 and histone deacetylases (Wade et al. 
1999; Zhang, Ng et al. 1999).  MBD3 was also shown to be a structural component of the 
NuRD complex (Zhang et al. 1999).  In addition to suppress transcription of methylated 
promoters, this complex can also remodel methylated chromatin (Ng et al. 1999; Feng 
and Zhang 2001).  These two methyl-CpG-binding complexes provide a link between 
DNA methylation-mediated transcriptional repression, histone deacetylation and 
chromatin remodeling. 
 
1.4.4.  Packaging of transcriptionally silent methylated 
chromatin 
 
The significance of the global waves of demethylation and remethylation is not known.  
However, recent developments suggest that demethylation in cleavage embryos could 
serve to decondense the chromatin to facilitate the expression of genes necessary for 
early development. In addition, the opening of the chromatin allows for repackaging 
into a “non-pluripotent conformation” that may act as a silencing mechanism for early 
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development and pluripotent genes.  The wave of remethylation that follows 
implantation is coordinated with chromatin condensation and somatic differentiation. 
DNA methylation at this stage may act as a mark to initiate chromatin assembly and 
help to maintain this structure during mitotic inheritance (Hashimshony et al. 2003).  
 
 DNA methylation patterns are read by methyl-binding transcriptional repressors 
that interact with histone deacetylase complexes that help remodel the chromatin into 
transcriptionally silent units.  The regulation of chromatin packaging involves a number 
of histones that can be selectively modified at their amino terminus.  These reversible 
reactions involve many histone modification enzymes and are very complex.  For 
example, acetylation of core histones can occur on lysine residues number 9, 14, 18 and 
23 of H3, lysines 5, 8, 12 and 16 of H4 and lysines of H2A and H2B.  The status of 
acetylation of histones has been shown to set the level of transcriptional activity of the 
chromatin (Strahl, B.D. and Allis C.D. 2000) and knockout of the Hdac1 gene, which 
encodes a histone deacetylase (HDAC), result in embryonic death at day E9.5 (Lagger, G. 
et al. 2002).  Interestingly, it has been shown that Dnmt1 and Dnmt3a can interact with 
HDACs and repress transcription (Burgers, W.A. et al. 2002).   
 
In addition to acetylation, methylation can occur on lysine residues 4, 9 27 and 79 
and arginines 2, 17 and 26 of H3 and lysine 20 and arginine 3 of H4.   However, less is 
known of the function of histone methylation but the evidence suggests that it may 
influence transcriptional activity.  Genetic knockout of the histone methyltransferases 
G9a and Suv39h1/  Suv39h2 results in embryonic lethality at day E9.5 and E14.5 
respectively (Peters et al. 2001).  G9a -/- mutant embryos have a loss of H3-K9 methylation 
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in euchromatin (decondensed, transcriptionally active regions) whereas Suv39h1/  
Suv39h2 double mutant embryos have a loss of H3-K9 methylation in heterochromatin 
(contains repetitive elements and other protein-coding genes and is generally 
transcriptionally silent) (Peters et al. 2001).  H3-K9 methylation has been associated with 
transcriptional silencing whereas H3-K4 methylation (as achieved by H3K4 histone 
methyltransferases such as MLL and SET7) has been correlated with active gene 
expression (Jenuwein and Allis 2001; Zhang and Reinberg 2001).  The identification of 
several H3-K9 methyltransferases in mammals indicate that specific histone 
methyltransferases may be targeted to different regions in the genome. 
 
All modifications of DNA and histones require that the chromatin be accessible.  
ATP-dependent chromatin remodeling proteins with DNA helicase activities are present 
in mammalian cells and are necessary to give accessibility of DNA to DNA 
methyltransferases (Gibbons et al. 2000).  These enzymes use the energy from the 
hydrolysis of ATP to induce twists into the DNA that results in the formation of 
nucleosomes (Peterson 2002).  For example, genetic knockout of the lymphoid-specific 
helicase (Lsh), a member of the SNF2/ helicase family, results in global demethylation of 
genomic DNA at embryonic day E13.5 and post-natal death (Dennis et al. 2001).  Other 
studies have shown that chromatin-remodeling proteins play a very important role in 
mammalian development as demonstrated by several gene knockouts that result in 
lethal phenotypes at various stages of development (Li 2002).  The specific mechanisms 
that regulate the interaction between chromatin remodeling, histone modification and 
DNA methylation remain to be elucidated.   
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 Histone modifications may act to modify the structure and chemical reactivity of 
histones making them amenable for interactions with regulatory proteins such as HP1 
which binds to H3K9, (Lachner et al. 2001), the Polycomb repressor which binds to 
H3K27, (Cao et al. 2002) as well as transcriptional regulators which binds bromodomains 
of acetylated histones, (Jacobson et al. 2000; Owen et al. 2000). 
 
Although evidence is lacking in mammals, studies to date showed a link between 
histone methylation and DNA methylation in the filamentous fungus Neurospora crassa 
and Arabidopsis thaliana (Tamaru and Selker 2001; Jackson et al. 2002).  Specifically, 
functional mutations of histone methyltransferases resulted in loss of DNA methylation.  
In addition, Suv39h-mediated methylation of H3K9 directs DNA methylation to major 
satellite repeats at pericentric heterochromatin in mammals (Lehnertz et al. 2003).  It is 
still unclear how histone methylation may regulate DNA methylation.  Interestingly, 
reduction of cytosine methylation leads to an increase of H3K9 and H3K14 acetylation 
and H3K4 methylation while causing a decrease in H3K9 methylation in mammals 
(Nguyen et al. 2001; Bachman et al. 2003).  The potential cross-regulation and inter-
dependence between DNA methylation and histone methylation remains to be clarified. 
 
1.4.5.  Is there a histone code? 
 
There is considerable evidence supporting the histone code hypothesis.  The 
identification of proteins capable of writing a potential code on histone tails and factors 
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capable of reading this code and influence gene transcription strongly support this idea.  
This hypothesis has generated considerable interest and effort is on-going to decipher 
the code so that histone tails can be read with reasonable predictability outcomes in any 
region of the genome.  The complete elucidation of the code will, however, take 
significantly more understanding of the complex dynamics of histone modification in 
gene regulation.  Such an understanding will be important to develop treatment for 
diseases stemming from defects in histone modifications and of transcriptional regulator 
proteins interacting with these factors.    
 
 
1.5. Methylation and disease 
 
A number of disorders have been associated with methylation-related 
abnormalities. Such diseases can be classified into methylation pathways deficiencies 
such as methyltransferase mutations or into deficiencies related to target genes of 
methylation such as imprinted genes and tumor suppressor genes.  Methylation 
aberrations have also been observed in a wide variety of cancer types and may play a 
role in disease progression through various mechanisms. 
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1.5.1.  Deficiencies of methylation pathways 
 
A number of diseases are caused by genetic mutations in enzymes that play key roles in 
methylation pathways.  These include ICF, Rett and fragile X syndrome.  The ICF 
syndrome (immunodeficiency, centromeric region instability, and facial anomalies 
syndrome) is a rare autosomal recessive disease.  In addition to the many developmental 
defects and mental retardation, an interesting characteristic is the presence of 
multibranched, deleted or duplicated chromosome arms, and centromeric breakage. 
 These regions are normally heavily methylated in somatic cells but are hypomethylated 
in ICF cells suggesting that methylation is important for centromeric structure and 
stability.  It has been shown that ICF syndrome is linked to a null mutation in the 
DNMT3B gene which may be important to maintain methylation at centromeres.   
 
The Rett syndrome (RTT) is an X-linked dominant disorder and is a very common 
cause of mental retardation in females (1/ 10 000).  A large proportion of Rett patients 
are heterozygous for mutations in the MECP2 gene, which encodes a methyl CpG-
binding protein that is X-linked (Guy et al. 2001).  Females develop normally until 6 to 18 
months of age but then lose speech, voluntary movements and hand skills (Guy et al. 
2001).  Knockout of MeCP2 in post-natal brains results in a phenotype similar to that of 
Rett syndrome (Chen et al. 1998; Chen et al. 2001; Guy et al. 2001).  However, the 
mechanism responsible for this phenotype is unknown.   
 
 34
The Fragile X syndrome is the most common form of inherited mental retardation 
(1/ 5000 in males) after Down syndrome and affects mostly males (Kooy et al. 2000). 
 The syndrome is defined by cognitive impairment, enlarged testes and behavioral 
hyperactivity.  The gene associated with the syndrome, FMR1 (Fragile X Mental 
Retardation-1), contains a CGG repeat in the 5’ untranslated region (UTR) that is greatly 
amplified in the syndrome (more than 200 repeats compared to 5-50 in normal patients) 
(Verkerk et al. 1991). Expansion of the repeat causes methylation (Pieretti et al. 1991) and 
deacetylation (Coffee et al. 1999) of the repeat and surrounding sequences, including the 
FMR1 promoter, resulting in transcriptional suppression of the FMR1 gene. So the effect 
is indirect in this case.  Knockout of Fmr1 in mice results in mild, but consistent 
abnormalities, analogous to the clinical and pathological symptoms observed in human 
patients (Kooy 2003).  The product of the FMR1 gene is a ubiquitously expressed RNA-
binding protein that may be involved in selective RNA trafficking between the 
cytoplasm and the nucleus.  The connection between the function of the FMR1 protein 
and the syndrome is unclear and Fmr1 mouse models will be very useful in that respect 
(Kooy 2003). 
 
1.5.2.  Imprinted genes disorders 
 
Imprinted genes have been implicated in several diseases.  The Beckwith-
Wiedemann syndrome (BWS) is a clinical condition associated with somatic fetal 
overgrowth and variable predisposition to cancer.  The most common molecular 
abnormality in this syndrome is biallelic expression of the imprinted gene insulin 
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growth factor-2 (Igf2 – an important fetal growth factor) which occurs in 80 % of all 
patients without cytogenetic abnormalities (Weksberg et al. 1993).  Overexpression of 
Igf2 in transgenic mice confers most of the phenotype of BWS suggesting a direct role for 
elevated Igf2 levels in BWS.  Experiments suggest that mutations in some of the 
imprinted genes surrounding Igf2 may act as transcriptional activators of this gene in 
BWS (Reik and Maher 1997).  
 
The Prader-Willi syndrome (PWS) is another condition which is linked to 
abnormal imprinted gene expression.  It is a developmental and behavioral disease 
linked to de novo intrachromosome deletions within an imprinted domain that causes 
altered expression of multiple contiguous imprinted genes.  The end result is generally a 
loss of expression of paternally inherited alleles.  It is characterized by hypotonia, 
respiratory distress, hyperphagia, small hands and feet and mental retardation, temper 
tantrums, and obsessive-compulsive mannerisms (Nicholls and Knepper 2001). 
 
 A closely linked disorder, the Angelman syndrome (AS), also results in 
intrachromosomal deletions within the same region linked to PWS but is in contrast 
associated with losses of maternally inherited alleles.  Evidence indicates that the 
disorder results from disrupted expression of the maternal UBE3A brain-specific 
expression. (Nicholls and Knepper 2001).  The syndrome is characterized by 
developmental delay, severe mental retardation with a lack of speech, movement ataxia, 
hyperactivity, seizures, aggressive behavior and excessive inappropriate laughter (Jiang 
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et al. 1999).  While PWS and AS result most frequently from LOH of the functional allele, 
a number of other cases appear entirely epigenetic.   
 
1.5.3.  Methylation and cancer 
 
Methylation has been postulated to play a role in cancer for many decades.  DNA 
methylation patterns are significantly altered in many tumor types and include both 
hypermethylation and hypomethylation.  The former is usually localized to specific 
regions surrounding gene promoters while the latter is genome-wide. Promoter 
hypermethylation is the most well categorized epigenetic change to occur in tumors.  It 
is found in virtually every type of human neoplasm and is associated with inappropriate 
gene silencing. A large number of tumor-suppressor genes have been shown to be 
silenced by hypermethylation in cancer and include RB (Greger et al. 1989), VHL 
(Herman et al. 1994) and p16ink4a (Gonzalez-Zulueta et al. 1995; Merlo et al. 1995) as 
well as DNA repair genes such as MLH1 (Baylin et al. 2001).  Interestingly, promoter 
silencing by hypermethylation is at least as common as the disruption of classic tumor-
suppressor genes in human cancer by mutation.  Another effect of hypermethylation 
besides gene silencing is the higher frequency of point mutations that results from 
increased deamination of 5’-methylcytosine to uracil, resulting in a C⇐T mutation after 
the subsequent round of DNA replication (Jones et al. 1992; Laird and Jaenisch 1994).   
Indeed, CpG to TpG mutations account for many acquired somatic mutations that lead 
to cancer.  For example, the p53 gene displays such mutations in 50% of all inactivating 
 37
mutations in colon cancer and in 25% of cancers in general despite having only 4% of 
methyl CpG in its sequence (Rideout et al. 1990).   
 
The evidence linking hypomethylation to tumorigenesis also includes a 
considerable body of literature.  A large variety of different tumor types in mammals 
have been shown to be hypomethylated, in many cases in conjunction with local 
hypermethylation although the evidence that the two mechanisms are independent of 
each other is lacking (Ehrlich 2002).  Hypomethylation is as prevalent as 
hypermethylation in cancers but its potential role in tumorigenesis has not been well 
studied.  It is generally observed at repeated sequences such as LINES and other 
retrotransposons, centromeric repeats and to a lesser extent to specific genes (Ehrlich 
2002).  It has been suggested that reduction in S-adenosyl-L-methionine metabolism may 
induce hypomethylation and play an important role in carcinogenesis (Chiang et al. 
1996).  For example, reduced supply of methionine, folate and choline in rats, all 
precursors of S-adenosyl-L-methionine, leads to genomic hypomethylation, 
overexpression of c-H-ras, c-jun and c-myc and results in liver tumors (Simile et al. 1994).  
Similarly, methyl donor deficiencies is correlated with liver and colon tumors in humans 
(Giovannucci et al. 1993).  These experiments suggest a link between dietary factors and 
cancer and argue that hypomethylation may play a role in tumorigenesis.  It has been 
suggested that hypomethylation represents an early stage in the development of some 
tumors (Goelz et al. 1985). Surprisingly, hypomethylation reduces tumor number in 
APCmin mice suggesting a protective role against tumor formation (Laird et al. 1995). 
 While hypermethylation generally silences gene expression, it is unclear what the result 
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of hypomethylation might be in cancer development. Demethylation of genes silenced 
by methylation has not been frequently reported and evidence is lacking to support this 
mechanism.  Many experiments have suggested that hypomethylation promotes 
genomic instability.  It has been shown that hypomethylation in ES cells causes an 
increase in mutation rate and LOH by mitotic recombination (Chen et al. 1998).  In a 
sterile hybrid obtained from two species of kangaroos, global hypomethylation was 
linked to chromosomal rearrangements including telomere elongation and various 
translocations (O'Neill et al. 2001).  In addition, in the fungus Neurospora crassa, knockout 
of the main DNA methyltransferase (dim-2) resulted in chromosome instability (Foss et 
al. 1995).  The association of hypomethylation with histone acetylation favors an open 
chromatin conformation which might render the genome more prone to recombination 
events than tightly packed DNA.  To date, no clear evidence exists to suggest that 
hypomethylation leads to genomic instability in  vivo. 
 
 
1.5.4. Altered hypomethylation in cancer: cause or consequence?  
 
Despite all the evidence linking changes of methylation patterns and 
tumorigenesis, it is unknown whether methylation plays a causal role in cancer 
development.  Hypomethylating agents have been shown to induce tumorigenesis in 
rodents but most of these compounds are mutagenic, making it difficult to attribute a 
phenotype to the hypomethylated state or to mutations induced by the drug itself. To 
establish a causal relationship between hypomethylation and cancer, a genetic approach 
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resulting in global hypomethylation in vivo must be developed.  So far, null mutations 
for all methyltransferases have resulted in death during embryogenesis or soon after 
birth, making it difficult to engineer an experimental model of hypomethylation.  A T 
cell-specific knockout of Dnmt1 was studied in mice and caused death of all mature T 
cells (Lee et al. 2001).  In addition, knockout of Dnmt1 in mouse embryonic fibroblasts 
also caused cell death (Jackson-Grusby et al. 2001).  These results are consistent with 
methylation being required for somatic differentiation and begs for a new strategy for 
the design of an animal model of hypomethylation. 
 
1.6.  Study of the role of hypomethylation in development and 
cancer 
 
 The body of this thesis project aimed at developing a genetic system to study the 
effect of hypomethylation in development and cancer.  A strategy was designed to 
generate a hypomorphic allele of the maintenance methyltransferase Dnmt1 to be used 
in a new experimental model.   
 
The Dnmt1 gene can produce two different protein isoforms.  The shorter isoform 
is present in oocytes and early embryos whereas the longer isoform is present in 
postimplantation embryos and in adult tissues.  While it has been demonstrated that the 
longer isoform is required for embryonic development and survival (Li et al. 1992), the 
exact structure and function of the shorter isoform is unknown. Therefore, structural and 
functional analyses of this protein was undertaken.  Results showed that this shorter 
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isoform was generated from an ATG translational start site in exon 4 of the Dnmt1 gene 
and was capable of remethylating Dnmt1 null ES cells (Chapter 2).   
 
Experiments were designed to specifically address the effect of reduced levels of 
the Dnmt1 gene products in vivo.  Mice containing a weak Dnmt1 allele were engineered.  
The lower Dnmt1 levels in the animals were found to cause global genomic 
hypomethylation.  The effect of hypomethylation on development and cancer was 
studied using two approaches.   
 
In a first approach, we studied the effect of reduced levels of both Dnmt1 isoform 
on genomic methylation during embryogenesis by using a methylation-sensitive 
reporter allele (Chapter 3).  These results showed that the shorter maternal Dnmt1 
isoform was important to maintain the methylation of this reporter allele in cleavage 
embryos.  In contrast, the longer Dnmt1 isoform was important in maintaining 
methylation patterns in postimplantation embryogenesis.  Furthermore, changes in 
methylation patterns resulting from lower levels of either isoform were stably inherited 
in the adult.  Thus, interference with methylation pathways during gestation such as 
with dietary factors may result in permanent changes that may affect gene expression 
(Wolff  et al. 1998).   
 
In the second approach, the effect of hypomethylation on disease was 
investigated by aging Dnmt1 hypomorphic mice and monitoring their health for 
symptoms manifestation (Chapter 4).  After a few months of age, the vast majority of 
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these hypomethylated mice developed aggressive thymic lymphomas, demonstrating 
that hypomethylation can cause cancer.  The mechanism of tumor formation was further 
investigated and whole chromosome 15 duplications were implicated as one of the steps 
leading to tumorigenesis.   The oncogene c-myc, which is present on chromosome 15 was 
activated in these tumors.  In contrast, in tumors where chromosome 15 was not 
duplicated, c-myc was not overexpressed suggesting that c-myc overexpression was 
caused by chromosome 15 duplication.  Additional analyses of these tumors using gene 
expression arrays showed that another oncogene, Notch-1, was also overexpressed in all 
tumors.  The mechanism of Notch-1 activation was found to be an IAP insertion near the 
transmembrane region of the Notch-1 gene.  Insertion of these IAP caused the expression 
of truncated transcripts of Notch-1 that are known to carry oncogenic properties.  
Consistent with these findings, c-myc and Notch-1 have been shown to collaborate to 
induce the formation of thymic tumors in vivo (Pear et al. 1996).  Thus, hypomethylation 
can induce tumorigenesis by at least two mechanisms: insertional mutagenesis of weak 
retroviral elements and whole chromosome instability.  The effect of hypomethylation 
on chromosome stability was also shown in a different study in which the hypomorphic 
Dnmt1 allele was introduced in a tumor prone mouse strain (Annex).  In this case, 
hypomethylation accelerated tumor formation and whole chromosome loss was shown 
to contribute to the disease phenotype. 
 
The work presented here further emphasizes the importance of epigenetic 
changes in development and disease, in particular since patterns of methylation can be 
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modulated by environmental factors.  The nature of DNA methylation as a reversible 
modification also makes it an interesting approach for developing new therapies.   
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In this work, the effect of hypomethylation on mammalian development and 
cancer was investigated by lowering the levels of Dnmt1 in embryogenesis and in the 
adult.  A new Dnmt1 isoform (Dnmt1o) was characterized in oocytes and cleavage 
embryos and carried DNA maintenance activity in ES cells.  Functional analysis of this 
isoform in vivo suggested a role for Dnmt1o in maintaining IAP methylation in early 
embryogenesis, whereas the longer Dnmt1 isoform was important for maintaining IAP 
methylation in postimplantation embryos.  Reduction of the activity of the Dnmt1 gene 
in adult mice, which normally expresses the longer isoform, resulted in global genomic 
hypomethylation including at IAPs and development of tumors after a few months of 
age. 
 
Thus, changes in the degree of methylation by reduction of Dnmt1 levels can 
lead to stable modifications of methylation patterns and disease.  In the case of the 
Dnmt1 chip/- mice, reduced Dnmt1 levels are present throughout the life of the animal 
and results in genomic hypomethylation.  In addition, the methylation changes 
resulting from lowered Dnmt1 levels in early or late embryogenesis resulted in 
permanent changes in methylation patterns in the adult as evidenced by the coat color 
changes.    
 
In addition to inherit such embryonic changes in methylation, mammals can also 
inherit changes in chromatin structure, as a result of altered DNA methylation.  Indeed, 
postimplantation remethylation is followed by chromatin packaging which is 
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established based on the methylation state and is then stably inherited in the adult 
(Hashimshony, Zhang et al. 2003).   Changes of methylation during the chromatin 
packaging stage or prior to that stage may impair chromatin assembly and proper 
execution of subsequent developmental programs.   
 
Since adult cells originate from a limited number of cells in the embryo, changes 
in methylation patterns early on may be more crucial than during the adult stage.  
Thus, care must be taken that the levels of Dnmt1 be well regulated throughout the 
entire life of the animal as changes as early as embryogenesis may result in permanent 
changes that may cause disease later in life. Of importance is the effect of 
environmental factors on the integrity of embryonic genomic methylation.   
 
5.1. Environmental factors influencing DNA methylation 
 
It has been shown that methylation and expression of the Aiapy locus in embryos 
is sensitive to L-methionine intake by pregnant mothers (Wolff et al. 1998; Cooney et al. 
2002).  In humans, much of the evidence linking the diet to DNA methylation changes 
has been obtained from the adult stage.  Dietary supplements such as folate or vitamins 
that affect the activity of enzymes that supply methyl groups for various cellular 
methylation processes can influence the rate of disease manifestation (Van den Veyver 
2002) and the rate of colon cancer incidence (Giovannucci et al. 1993).  Lower levels of 
folate intake has been associated with genomic instability (Blount et al. 1997; Jacob 
1999) and genomic hypomethylation (Friso et al. 2002).  Furthermore, methyl donor-
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deficient diet has been shown to induce liver cancer associated with hypomethylation 
and overexpression of c-ras, c-myc or c-fos (Poirier et al. 1990; Dizik et al. 1991; Wainfan 
and Poirier 1992).  An interesting study of the effect of diet on methylation changes in 
human pregnancy showed that during a winter famine in Holland in the Second World 
War, normal daughters born during that period were much likely to have smaller 
babies (John and Surani 1999).  The latter has been postulated to have an epigenetic 
basis and might be consistent with a transgenerational inheritance of epigenetic state of 
the same sort observed at the Aiapy locus.  A number of other diseases which are 
inherited but do not follow Mendelian inheritance have also been postulated to have an 
epigenetic component and include multiple sclerosis, diabetes, rheumatoid arthritis and 
cancer (Petronis 2001).   
 
In contrast to embryogenesis, overall methylation patterns do not vary 
significantly in the adult.  However, aging has been associated with both gains and 
losses of methylation.  General hypomethylation is normally seen in adults (Mays-
Hoopes et al. 1986; Wilson et al. 1987) and progressive losses of methylation are also 
observed in fibroblasts in vitro (Wilson and Jones 1983).  CpG islands hypermethylation 
is also observed with aging such as the estrogen receptor, IGF2 and MYOD (Issa et al. 
1994; Issa 2000).  In fact, aging is one of the most important risk factor of cancer and 
CpG island hypermethylation may play a crucial role in the development of tumors in 
some individuals (Jones and Laird 1999; Toyota et al. 1999).  Thus, while genetic 
mutations have been clearly shown to cause and explain diseases, it has never been 
shown whether epigenetic changes can actually initiate disease or whether these 
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changes simply represent a consequence of cellular malfunctions.   Because methylation 
patterns, especially during embryogenesis, are liable to be altered by the diet, an 
understanding of the impact of such changes in development and disease would be 
relevant.   Although highly speculative, it is possible that DNA methylation patterns 
may be altered by additional environmental stimuli.  For example, temperature 
influences vernalization in plants growing at high altitudes and has been suggested to 
have an epigenetic component (Sheldon et al. 1999; Sheldon et al. 2000).  Indeed, the 
FLOWERING LOCUS C (FLC) which appears to play an important role in the early 
flowering induced by low temperatures is thought to be regulated by DNA methylation 
(Sheldon et al. 1999; Sheldon et al. 2000).   
 
5.2.  DNA methylation, genomic instability and cancer 
 
It has not been established whether DNA methylation plays a causal role in any 
of these diseases or whether it reflects the cellular diseased state.  The best studied case 
in which DNA methylation abnormalities are consistently found is cancer. 
 
The link between methylation changes and cancer has been established decades 
ago.  However, it was never demonstrated whether hyper- or hypomethylation play a 
causal role in tumor formation.  The results of this work clearly show that 
hypomethylation can induce tumorigenesis in mice.  Hypomethylation induces 
chromosomal instability, resulting in the gain of chromosome 15 and additional gains 
of chromosome 14 in some tumors.  Trisomy of chromosome 15 was correlated with c-
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myc overexpression suggesting a role for this chromosome duplication in the oncogenic 
overexpression.  Gene expression array analysis of tumor RNAs showed that the 
oncogene Notch-1 was also overexpressed in all tumors.  The gene was found to 
contain IAP insertions which drive the expression of smaller species of oncogenic 
Notch-1.  Thus, hypomethylation induced tumorigenesis in this model by 2 
mechanisms: chromosomal instability and insertional mutagenesis.  The potential for 
hypomethylation to induce tumor formation by a genomic instability mechanism was 
tested in a different study where the effect of genomic hypomethylation on a previously 
described tumor-prone model was tested (see Annex part A). In this model, animals 
heterozygous for null mutations of the linked tumor suppressor genes for p53 and NF1 
(cis conformation) develop sarcomas after about 4 months of age.  The mechanism of 
tumorigenesis in these mice has been shown to be LOH of the wild-type allele of p53 
and NF1.  Because both genes are closely linked on chromosome 11, LOH at that locus 
results in the loss of both tumor suppressors genes.  Induction of hypomethylation in 
this tumor model by breeding in the Dnmt1chip and Dnmt1 null alleles resulted in a 
quicker formation of sarcomas suggesting that hypomethylation increases the rate of 
tumorigenesis in this model.  Using markers specific for either allele, the mechanism of 
tumor formation was found to be whole chromosome LOH.  To measure the mutation 
rate of tumor formation, embryonic fibroblasts were obtained from Dnmt1 chip/-; p53+/- / 
Nf1 +/- (cis) and an assay was developed to measure the rate of foci formation on agar 
plates.  The results showed that hypomethylation caused a 2 fold induction of the 
mutation rate.  The results of these experiments emphasize that hypomethylation 
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induces chromosome instability in mice and are consistent with the results obtained in 
the Dnmt1 chip/- mice. 
 
These results are consistent with the chromosomal instability observed in ICF 
syndrome where DNMT3B is mutated and centromeres becomes hypomethylated (Xu 
et al. 1999; Ehrlich et al. 2001).  Dnmt3b knockout in mice causes demethylation of the 
centromeric minor satellite repeats, suggesting that methylation of centromere repeats 
may play an important role in the maintenance of genomic stability (Okano et al. 1999).  
Similarly, induction  of demethylation in cultured cells by 5-aza-2’-deoxycitidine causes 
elongation of the centromeric or juxtacentromeric regions of the same chromosomes 
that are affected in ICF (Jeanpierre et al. 1993).  In addition, a homozygous null 
mutation of the Dnmt1 gene in ES cells causes demethylation and a 5 to 10 fold increase 
in mutation rate (Chen et al. 1998) which was attributed to a higher rate of mitotic 
recombination.   
 
5.3.  Clinical relevance 
 
Previous results have shown that in contrast to our results, hypomethylation was 
protective against tumor formation in an intestinal tumor model (Laird et al. 1995). 
 Thus, hypomethylation may protect against tumorigenesis in certain cell types but at 
the same time may promote cancer in other cell types such as T cells.  Hypomethylating 
agents such as 5-aza-2’-deoxycitidine (ex. Decitabine) have been used in the clinic and 
shown good promises for the treatment of myelodysplastic syndrome (MDS) and acute 
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myeloid leukemia (AML).  In addition, inhibitors of histone deacetylases (HDAC) have 
also shown good promises (Ex. SAHA) and several groups are actively pursuing new 
drugs. Studies also suggest that a combination treatment of both 5-aza-deoxycytidine 
and TSA (trichostatin A), a drug that inhibits HDAC activity, cause a more effective 
reactivation of silenced tumor suppressor genes (Cameron et al. 1999).  Many other 
histone- and chromatin modification enzymes have been shown to participate in 
tumorigenesis and new therapeutic approaches are being investigated. 
 
Although some of these drugs, such as 5-aza-dC and HDAC inhibitors have 
shown exciting promises as cancer therapeutics, caution should be exercised in using 
them as prophylactics.  While these compounds may have positive effects in treatment, 
it should be remembered that they might also have deleterious effects in other tissues 
and induce cancer.  The combination of both hypomethylating agents and compounds 
which aim at modifying chromatin associated proteins might represent a better solution 
than a single drug approach since the concentration of each drug may potentially be 
lowered to reduce toxicity and prevent the development of diseases associated with 
methylation abnormalities.  These drugs could also be used in combination with 
“smart” drugs, aimed at inhibiting specific oncogenes.  The reversibility of epigenetic 
changes makes epigenetic therapy a sensible strategy.  Although DNA 
hypomethylation agents are more likely to affect global levels of methylation, drugs 
aimed at histone modifying enzymes may display more restrained tissue-specific effects 
and therefore may prove less toxic.  The combination of both may thus help to reduce 
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toxicity, improve effectiveness and increase tissue-specificity of drugs aimed at treating 
many diseases. 
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Role of Notch-1 in Hypomethylation-
Mediated Tumorigenesis 
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To look for factors that collaborate with c-myc in promoting tumorigenesis in 
Dnmt1 chip/- tumors, we compared the expression profile of RNA from these tumors to 
that of either wild-type thymus RNA or CD4+/CD8+ wild-type cells using expression 
arrays.  As expected, Dnmt1 levels were reduced (5 fold) in the hypomethylated tumors 
and c-myc was overexpressed (3 fold; Table 1).  The results further showed that Notch-
1, a protein which regulates T cell development and which has also been shown to act 
as an oncogene was one of the most overexpressed mRNA in all tumors (6-9 fold).  In 
addition, two downstream targets of Notch-1, hairpin enhancer of split (HES-1) and 
Deltex were also overexpressed.  These genes are normally activated by Notch-1 and 
their overexpression is consistent with Notch-1 overexpression.   
 
 
 
Table 1.  Relative gene expression in Dnmt1 chip/- tumors and pre-tumor thymuses.  All 
gene expression levels are relative to the levels of wild type thymuses which have been 
arbitrarily set to 1.  “Thymus mut” represents Dnmt1 chip/- pre-tumor thymuses, Dnmt1 
null Fibroblasts” are mouse embryonic fibroblasts in which Dnmt1 was looped out by 
CRE resulting in the loss of all functional Dnmt1 alleles, “Thymomas Hypo CH3a” and 
“Thymomas Hypo CH3b” represent 2 independent experiments using 4 different Dnmt1 
chip/- tumors in each case, “Thymomas Mov-1” are thymic lymphomas from viremic 
Mov-1 mice and “CD4/ CD8 WT” are CD4+/ CD8+ FACS-sorted cells from wild type 
mice.  The numbers represent an average fold induction over 4-6 samples. 
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Elevated levels of Notch-1 were further confirmed by immunoblot analysis 
(Figure 1).  In contrast, Notch-1 overexpression was not detected in hypomethylated 
pre-tumor thymuses, showing that hypomethylation by itself is not sufficient to trigger 
increased levels of Notch-1 (data not shown). 
 
 
 
Figure 1.  Overexpression of Notch-1 in Dnmt1 chip/- tumor cell lines.  
Western blot using a Notch-1 antibody against protein extracts from either 
wild type thymus (WT lane) or from Dnmt1 chip/- cell lines (#15 and #18 
lanes).  The Notch-1 signal is elevated in both cell lines even if the WT lane 
was overloaded by 50% (1.5x). 
 
 
We next sought to characterize the nature of Notch-1 overexpression.  Since the 
CGH analysis of the hypomethylated tumors suggested that the copy number of 
chromosome 2 (on which Notch-1 resides) was normal (see Chapter 4), we tested 
whether the Notch-1 locus might harbor smaller genomic rearrangements, undetectable 
by CGH.  We isolated a mouse Notch-1 genomic BAC and used it as a probe against 
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interphase spreads of cell lines derived from hypomethylated tumors.  DNA FISH 
analysis revealed the presence of 2 dots per cells on average,  thus ruling out 
duplications or amplifications (Figure 2).   
 
To test whether discrete genomic rearrangements occurred at the Notch-1 locus, 
we performed a restriction mapping analysis of the genomic locus.  Southern analyses 
revealed the presence of abnormal restriction fragments in 6/19 tumors, consistent with 
genomic rearrangements (data not shown).   
 
Since the band expected from the wild-type allele was found in all of these 
samples, only one allele would be expected to contain the rearrangement.  To 
investigate whether these monoallelic rearrangements were responsible for monoallelic 
overexpression of Notch-1 expression, we performed a RNA FISH analysis of 
interphase spreads from hypomethylated tumor-derived cell lines using a Notch-1 BAC 
as a probe.  Results showed that most cells contained a weaker and a brighter 
fluorescent dot compared with wild-type cells which contain 2 weak fluorescent dots.  
These results suggest that one of the two Notch-1 alleles in the tumor cells is expressed 
at higher levels than the other, a result that is consistent with the Southern data 
showing rearrangement at only one allele.  The possibility that this rearranged allele is 
responsible for the increased expressed observed by FISH is supported by the Northern 
analyses which show that the smaller transcripts are found in larger amounts (A. Eden, 
personal communication). 
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Figure 2.  DNA and RNA FISH of Notch-1 on wild type and Dnmt1 chip/- 
tumor cells.  A BAC containing the mouse Notch-1 locus was used as a probe 
for DNA FISH (upper panels) or RNA FISH (lower panels) against wild type 
thymus cells (left) or a Dnmt1 chip/- tumor cell line (right).  On average, two 
dots of equal intensities were present in each cell nucleus in the DNA FISH.  
In contrast, Notch-1 mRNA signals were below detection in wild type cells 
but could be detected as 2 spots in the tumor cells: one weak spot and one 
brighter spot.  The width of each field (each panel) is 25 micrometer. 
 
 
To determine the nature of the transcripts resulting from these rearrangements, 
northern analyses were performed.  The results showed that most tumors contained the 
wild-type transcript and an additional species of RNA, indicating rearrangement at one 
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allele (A. Eden, personal communication).  In addition, these smaller RNA species were 
found in larger amounts than the endogenous transcript, suggesting that the 
rearranged allele is the one causing overexpression.  To characterize the rearrangement, 
restriction mapping was used to fine-map these new changes within a 1 kb DNA 
fragment.  A long-range PCR assay was developed to amplify this DNA segment and 
sequencing of 8 PCR-amplified DNA fragments from this rearranged region showed 
the presence of IAP insertions (A. Eden, personal communication).   
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Discussion 
 
 These results emphasize that endogenous non-replicative retroviruses may 
play a role in tumorigenesis in mice.  Although IAP insertions have been characterized 
at various locus before in the mouse genome, this is the first demonstration that 
activation of an IAP by hypomethylation may lead to insertions that may play a role in 
tumorigenesis. 
 
Induction of viremia in c-myc transgenic mice results in activation of Notch-1 in 
many cases and development of thymic tumors (1).  Notch-1 translocations into the 
TCRb locus have also been observed in tumors in humans and the break point has been 
mapped to the same region upstream of the transmembrane domain.  The region is 
very rich in non-contiguous repeats that might be less stable.  It is also possible that the 
site is not less stable but rather is selected for because insertions in that specific locus 
may give a growth advantage.  Although IAP expression is elevated in hypomethylated 
tumors, the degree of overexpression is not as overwhelming as in Dnmt1 null 
fibroblasts.  This would thus suggest that the insertion site might be preferred and 
insertions can be detected even if IAP overexpression is not very high. 
 
Insertional mutagenesis caused by retroviruses is not a common mechanism of 
tumorigenesis in humans.  Nevertheless, the human genome contains 45% of 
retrotransposon-derived sequences and hypomethylation could lead to activation of 
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non-replicative retroelements  that could participate in the tumor process or in other 
diseases.   This interesting possibility remains to be further studied.   
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273, 32725 (1998), Gaudet, F., Talbot, D., Leonhardt, H., Jaenisch, R. 
 
I layed out all project aims.  I sequenced the promoter region of Dnmt1 (Fig. 1a-b) and 
identified new potential translation sites (Fig. 1c), tested the functionality of these ATG 
sites (Fig. 3a) and the ability of the Dnmt1 mutants to functionally complement Dnmt1 
null ES cells (Fig3. b), evaluated the development potential of those rescued ES cells by 
generating teratomas in vivo (Fig. 4a-b).  Finally I wrote the paper and made all the 
figures.  D. Talbot did the immunoblots on Fig. 2.  The sequencing of the N-terminus of 
Dnmt1 was performed by a core facility at MIT.   
 
 
Paper 2 
 
Dnmt1 Overexpression Causes Genomic Hypermethylation Loss of Imprinting, and 
Embryonic Lethality, Mol. Cell. Biol., 22, 2124 (2002), Biniszkiewicz, D., Gribnau, J., 
Ramsahoye, B., Gaudet, F., Eggan, K., Humpherys, D., Mastrangelo, M.A., Jun., Z., 
Walter, J., Jaenisch. 
 
I performed the immunoblots for Fig. 1b and Fig.  6b, both of which were critical to 
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